iShares Core S&P 500 ETF vs Nuwellis Inc — how do they compare? iShares Core S&P 500 ETF trades at $750.38, while Nuwellis Inc trades at $2.85 (market cap $1.09M). The key difference: iShares Core S&P 500 ETF is trading nearer its 52-week high, Nuwellis Inc nearer its low. Which is the better fit depends on your goals.
| IVV | NUWE | |
|---|---|---|
Sector | Broad Market / Factor | Technology |
52-Week High | $763.10 | $527.46 |
52-Week Low | $624.65 | $2.80 |
Market Cap | — | $1.09M |
Enterprise Value | — | -$722.58K |
Signals from Pluang's Aura AI — not financial advice
IVV, tracking the S&P 500, trades at $745.67, down 0.14% with a bearish technical signal from moving averages. The fund remains heavily weighted toward technology stocks, with recent news highlighting concentration risks and debates over valuation. A dividend of $2.00 is scheduled for June 2026, providing income amid market volatility.
Outlook is cautious due to technical weakness and high tech exposure, though long-term growth prospects from AI and earnings strength offer potential. Key risks include market concentration, valuation concerns, and macroeconomic shifts impacting broad index performance.
NUWE trades at $3.00, up 5.26% today, following a 35:1 reverse stock split effective June 26, 2026. The company shows a low P/E of 0.06 and P/S of 0.01, but fundamentals are weak with a -217.22% net income margin and negative ROE. Recent news highlights patent awards and pediatric market expansion, yet cash flow remains negative. Analyst coverage is limited with a split buy/hold consensus.
Outlook is speculative; growth depends on successful commercialization of Aquadex therapy and cost management. Key risks include persistent losses, high cash burn, and competitive pressures. Investors should weigh low valuation against execution risks in the medical technology sector.
Trailing returns across standard periods
Latest headlines on both assets
IVV tracks the performance of the S&P 500 Index, offering low-cost exposure to 500 of the largest US companies. It is a cornerstone for long-term investors seeking broad growth in the US stock market.
Read more on IVV →Nuwellis, Inc. is a medical device company focused on developing and commercializing fluid management solutions. The company's primary product is an ultrafiltration system used in hospitals to remove excess fluid from patients with fluid overload, often associated with conditions such as heart and kidney failure. Nuwellis aims to improve patient outcomes and reduce healthcare costs through its specialized, innovative therapies.
Read more on NUWE →